Search Results - "Zou, Hesong"

Favorable outcomes of front-line risk-adapted therapy in young patients with diffuse large B-cell lymphoma with clinically or biologically high-risk features by Zou, Hesong, Liu, Wei, Wang, Yi, Shan, Dandan, Xie, Ting, Li, Ru, Liu, Huimin, Huang, Wenyang, Fu, Mingwei, Wang, Tingyu, Lyu, Rui, Deng, Shuhui, Sui, Weiwei, Xu, Yan, Yi, Shuhua, An, Gang, Qiu, Lugui, Zou, Dehui

“…[...]approximately one-third of DLBCL cases continue to experience disease progression, resulting in long-term survival ranging from 50% to 60%. [...]we…”
Get full text

Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy by Zou, Hesong, Liu, Wei, Wang, Xiaojuan, Wang, Yi, Wang, Chunyang, Qiu, Chen, Liu, Huimin, Shan, Dandan, Xie, Ting, Huang, Wenyang, Sui, Weiwei, Yi, Shuhua, An, Gang, Xu, Yan, Ma, Tonghui, Wang, Jianxiang, Qiu, Lugui, Zou, Dehui

“…BackgroundOver 50% of patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) receiving CD19-targeted chimeric antigen receptor (CAR19) T-cell…”
Get full text

Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma by Liu, Wei, Liu, Wei, Zou, Hesong, Chen, Lianting, Huang, Wenyang, Lv, Rui, Xu, Yan, Liu, Huimin, Shi, Yin, Wang, Kefei, Wang, Yi, Xiong, Wenjie, Deng, Shuhui, Yi, Shuhua, Sui, Weiwei, Peng, Guangxin, Ma, Yueshen, Wang, Huijun, Lv, Lulu, Wang, Jianxiang, Wei, Jun, Qiu, Lugui, Zheng, Wenting, Zou, Dehui

“…BackgroundApproximately two-thirds of patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) do not respond to or relapse after anti-CD19…”
Get full text

P1162: FRONT‐LINE RISK‐ADAPTED THERAPY PRESENTED FAVORABLE OUTCOMES FOR YOUNG PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA: RESULTS FROM A CONSECUTIVE COHORT IN CHINA by Zou, Hesong, Liu, Wei, Shan, Dandan, Liu, Huimin, Xie, Ting, Huang, Wenyang, Wang, Yi, Yi, Shuhua, Xu, Yan, An, Gang, Sui, Weiwei, Wang, Tingyu, Qiu, Lugui, Zou, Dehui

Get full text

Long-Term Activity of Combining CNCT19 with HDT/ASCT in Refractory Large B-Cell Lymphoma: Two-Year Follow-up of a Prospective Phase 1/2 Clinical Trial by Liu, Wei, Zou, Hesong, Xu, Yan, Liu, Huimin, Du, Chenxing, Lv, Rui, Huang, Wenyang, Sui, Weiwei, Yi, Shuhua, Lv, Lulu, Qiu, Lugui, Wang, Jianxiang, Zou, Dehui

Get full text

A Retrospective, Matched Paired Analysis Comparing GBM/GBC Versus BEAM/Beac Conditioning Regimen for Autologous Stem Cell Transplantation in Non-Hodgkin's Lymphoma by Liu, Huimin, Zou, Hesong, Liu, Wei, Huang, Wenyang, Deng, Shuhui, Lv, Rui, Sui, Weiwei, Xu, Yan, Yi, Shuhua, Wang, Tingyu, Fu, Mingwei, An, Gang, Zhao, Yaozhong, Qiu, Lugui, Zou, Dehui

Get full text

Gemcitabine‐based conditioning compared to BEAM/BEAC conditioning prior to autologous stem cell transplantation for non‐Hodgkin lymphoma: No difference in outcomes by Liu, Huimin, Zou, Hesong, Shan, Dandan, Liu, Wei, Huang, Wenyang, Sui, Weiwei, Deng, Shuhui, Wang, Tingyu, Lv, Rui, Fu, Mingwei, Xu, Yan, Yi, Shuhua, An, Gang, Zhao, Yaozhong, Qiu, Lugui, Zou, Dehui

“…Background High‐dose chemotherapy followed by autologous stem cell transplantation (ASCT) remains an effective treatment for non‐Hodgkin lymphoma (NHL). The…”
Get full text